Evofem Biosciences, Inc. (EVFM): Entry into a Material Definitive Agreement
Evofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS NOTE MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHER
How this was made
The 30-second read
Why it matters
EVFM’s new debt includes 12% per annum interest compounded monthly, a 2% administration fee, and a $2,000 weekly monitoring fee, with all principal and accrued interest due at an 11-month maturity.
Market read
Traders can reassess EVFM’s liquidity and credit risk based on the newly disclosed financing terms and near-term fee burden.
What to watch
The filing excerpt does not include covenants, repayment schedule details beyond maturity, or whether this replaces prior obligations; those could materially change net credit impact.
Background
The 8-K reports entry into a material definitive agreement, including a promissory note and a direct financial obligation.
Ticker impact
Evofem entered a material definitive agreement via a $706,304 promissory note with 12% monthly-compounded interest and weekly monitoring fees.
Near-term downside bias as investors price higher financing costs and monitoring-fee cash burn; magnitude depends on EVFM’s existing cash runway.
The 8-K adds a concrete debt instrument (principal, interest rate, fees, maturity in 11 months) and specifies proceeds use for supplier payments tied to Phexx and Solosec, which is typically credit-negative for small-cap biotech.
Market effects
Highlights ongoing reliance on non-traditional financing structures in small-cap biotech, potentially reinforcing sector-wide liquidity concerns.
Limited direct regional spillover; counterparty is Israel-based but the obligation is on the US issuer.
Low; this is issuer-specific debt rather than a broad macro or cross-border deal affecting multiple companies.
Counterpoint
The note may be a bridge to keep supplier payments current for Phexx and Solosec, reducing operational disruption risk despite higher cost.
Key entities
- issuerEvofem Biosciences, Inc.
US-listed biotech company filing the 8-K for entry into a material definitive agreement and promissory note.
- lenderHUB CYBER SECURITY LTD.
Israel-formed holder/counterparty under the promissory note.
- productPhexx
Product referenced as the purpose for proceeds used to pay suppliers.
- productSolosec
Product referenced as the purpose for proceeds used to pay suppliers.
